Serono Taps Aussie Biotech For New MS Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Licensing deal includes up to $47 million per developed drug and full research funding.
You may also be interested in...
Infections, Death Fail To Stop Novartis’ Phase III MS Trial
“Confounding” factors in play; monitoring board gives green light to continue.
Fampridine-SR Phase III Data Support Filing For Multiple Sclerosis, Acorda Says
Company targets first quarter 2009 for NDA submission; will position Fampridine-SR as an add-on to immunomodulators.
Novartis’ Oral MS Drug Strong In Three-year Phase II Data
Side effects rang alarms early on, but disappeared over time.